Scarica l'app Stockscreener
2.95
1.99%
-0.06
Pre-mercato:
3.11
0.16
+5.42%
Precedente Chiudi:
$3.01
Aprire:
$3.31
Volume 24 ore:
2.94M
Relative Volume:
3.84
Capitalizzazione di mercato:
$93.09M
Reddito:
-
Utile/perdita netta:
$-69.00M
Rapporto P/E:
-1.0612
EPS:
-2.78
Flusso di cassa netto:
$-55.26M
1 W Prestazione:
+22.41%
1M Prestazione:
+24.47%
6M Prestazione:
+136.00%
1 anno Prestazione:
-53.17%
Intervallo 1D:
$2.86
$3.56
Intervallo di 1 settimana:
$2.2735
$3.56
Portata 52W:
$1.05
$8.00
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Nome
Acrivon Therapeutics Inc
Settore
Industria
Telefono
617-207-8979
Indirizzo
480 ARSENAL WAY, SUITE 100, WATERTOWN
Confronta ACRV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
2.95 | 94.98M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-05 | Ripresa | Piper Sandler | Overweight |
| 2025-01-31 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-12-15 | Ripresa | Jefferies | Buy |
| 2023-10-05 | Iniziato | Maxim Group | Buy |
| 2023-06-02 | Iniziato | Oppenheimer | Outperform |
| 2023-05-08 | Iniziato | BMO Capital Markets | Outperform |
| 2023-04-27 | Iniziato | Ladenburg Thalmann | Buy |
| 2023-04-20 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-12-12 | Iniziato | Jefferies | Buy |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Acrivon To Deliver Clinical Updates On ACR-368 And ACR-2316 Tomorrow; Stock Soars - Nasdaq
Acrivon Therapeutics to announce clinical update on Phase 2b ACR-368 studies - TipRanks
Acrivon Therapeutics to announce clinical update on phase 2b ACR-368 studies - MSN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Acrivon to provide clinical updates on cancer drug candidates By Investing.com - Investing.com South Africa
Acrivon Therapeutics to Release Clinical Data Updates on ACR-368 and ACR-2316 on January 8, 2026 - Quiver Quantitative
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - The Manila Times
New data on experimental cancer drugs ACR-368 and ACR-2316 coming - Stock Titan
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Head-To-Head Contrast: Acrivon Therapeutics (NASDAQ:ACRV) versus Ernexa Therapeutics (NASDAQ:ERNA) - Defense World
Is Acrivon Therapeutics Inc a good long term investmentEarnings Volatility Patterns & Multiply Your Assets With Time-Tested Picks - earlytimes.in
Trend Recap: Why retail investors pile into Acrivon Therapeutics Inc stockWeekly Stock Summary & Weekly Watchlist for Hot Stocks - moha.gov.vn
H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - MSN
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
Is Acrivon Therapeutics Inc. stock attractive for long term wealth buildingWeekly Trade Analysis & Growth-Oriented Investment Plans - Улправда
Acrivon Therapeutics (NASDAQ:ACRV) Rating Increased to Hold at Wall Street Zen - MarketBeat
What momentum indicators show for Acrivon Therapeutics Inc. stockEarnings Risk Report & Free Weekly Chart Analysis and Trade Guides - Улправда
Will Acrivon Therapeutics Inc. stock attract ESG investors2025 Short Interest & Reliable Trade Execution Plans - Улправда
Is Acrivon Therapeutics Inc. stock a good choice for value investorsQuarterly Profit Report & Safe Capital Allocation Plans - Улправда
Does Acrivon Therapeutics Inc. stock trade at a discount to peersMarket Trend Review & Verified Entry Point Detection - Улправда
What is the fair value of Acrivon Therapeutics Inc. stock nowMarket Activity Summary & Advanced Technical Signal Analysis - DonanımHaber
Why Acrivon Therapeutics Inc. stock could rally in 2025July 2025 Review & Fast Gain Stock Trading Tips - DonanımHaber
How Acrivon Therapeutics Inc. stock compares to market leadersJuly 2025 Volume & Daily Risk Controlled Trade Plans - DonanımHaber
Is Acrivon Therapeutics Inc. stock overvalued by current metricsWeekly Profit Recap & Low Drawdown Trading Techniques - Улправда
Acrivon Therapeutics, Inc.(NasdaqGM: ACRV) dropped from NASDAQ Biotechnology Index - marketscreener.com
Aug Catalysts: Does Acrivon Therapeutics Inc. stock trade at a discount to peersTrade Ideas & Comprehensive Market Scan Reports - ulpravda.ru
Inflation Data: Is Acrivon Therapeutics Inc. stock a good choice for value investorsProduct Launch & High Accuracy Investment Signals - Улправда
CEO Change: What momentum indicators show for Acrivon Therapeutics Inc. stockDividend Hike & High Accuracy Buy Signal Tips - Улправда
Acrivon to provide ACR-368, ACR-2316 clinical data in January - MSN
Acrivon to provide clinical data updates for cancer drugs in January - Investing.com Nigeria
Acrivon Therapeutics to Provide Clinical Data and Updates on ACR-368 and ACR-2316 in January 2026 - Quiver Quantitative
UPDATE -- Acrivon Therapeutics to Announce Clinical Update - GlobeNewswire
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - Yahoo Finance
Acrivon Therapeutics to announce clinical update - marketscreener.com
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates - The Manila Times
Acrivon Therapeutics to Announce Clinical Update on Its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates - 富途牛牛
Acrivon Therapeutics Earnings Notes - Trefis
Acrivon Therapeutics (NASDAQ:ACRV) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Cantor Fitzgerald sets Acrivon stock to Overweight on AP3 platform - MSN
3 Promising Penny Stocks With Market Caps Over $70M - Sahm
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Holdings of Acrivon Therapeutics Inc (ACRV) are aligned with the stars - setenews.com
Volume Report: How Acrivon Therapeutics Inc stock reacts to bond yields2025 Historical Comparison & Growth-Oriented Investment Plans - moha.gov.vn
What drives Acrivon Therapeutics Inc stock priceTrendline Breakouts & Low Cost Capital Growth - earlytimes.in
SBI Cards and Payment Services Limited Stages Intraday Comeback Trend Change - earlytimes.in
How Acrivon Therapeutics Inc. stock reacts to bond yieldsBond Market & AI Forecasted Entry and Exit Points - Newser
ACRV SEC FilingsAcrivon Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Get in on Acrivon Therapeutics Inc’s (ACRV) buy-in window today! - setenews.com
Acrivon Therapeutics Inc Azioni (ACRV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):